首页 / 院系成果 / 成果详情页

Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial  期刊论文  

  • 编号：
    0D09B99657F0B42E88B8E370310ECCAB
  • 作者：
    Zhu, Dalong#*[1]Li, Xiaoying#[2]Ma, Jianhua[3];Zeng, Jiao''e[4];Gan, Shenglian[5];Dong, Xiaolin[6];Yang, Jing[7];Lin, Xiaohong[8];Cai, Hanqing[9];Song, Weihong[10];Li, Xuefeng[11];Zhang, Keqin[12];Zhang, Qiu[13];Lu, Yibing[14];Bu, Ruifang[15];Shao, Huige[16];Wang, Guixia[17];Yuan, Guoyue[18];Ran, Xingwu[19];Liao, Lin[20,21];Zhao, Wenjuan[22];Li, Ping[1];Sun, Li[23];Shi, Lixin[24];Jiang, Zhaoshun[25];Xue, Yaoming[26];Jiang, Hongwei[27,28];Li, Quanmin[29];Li, Zongbao[30];Fu, Maoxiong[31];Liang, Zerong[32];Guo, Lian[33];Liu, Ming[34];Xu, Chun[35];Li, Wenhui[36];Yu, Xuefeng[37];Qin, Guijun[38];Yang, Zhou[39];Su, Benli[40];Zeng, Longyi[41];Geng, Houfa[42];Shi, Yongquan[43];Zhao, Yu[44];Zhang, Yi[44];Yang, Wenying(杨文英)*[45]Chen, Li*[44]
  • 语种：
    英文
  • 期刊：
    NATURE MEDICINE ISSN：1078-8956 2022 年 28 卷 5 期 (965 - +) ; MAY
  • 收录：
     
  • 摘要：

    Improving glucose sensitivity remains an unmet medical need in treating type 2 diabetes (T2D). Dorzagliatin is a dual-acting, orally bioavailable glucokinase activator that enhances glucokinase activity in a glucose-dependent manner, improves glucose-stimulated insulin secretion and demonstrates effects on glycemic control in patients with T2D. We report the findings of a randomized, double-blind, placebo-controlled phase 3 clinical trial to evaluate the efficacy and safety of dorzagliatin in patients with T2D. Eligible drug-naive patients with T2D (n = 463) were randomly assigned to the dorzagliatin or placebo group at a ratio of 2:1 for 24 weeks of double-blind treatment, followed by 28 weeks of open-label treatment with dorzagliatin for all patients. The primary efficacy endpoint was the change in glycated hemoglobin from baseline to week 24. Safety was assessed throughout the trial. At week 24, the least-squares mean change in glycated hemoglobin from baseline (95% confidence interval) was -1.07% (-1.19%, -0.95%) in the dorzagliatin group and -0.50% (-0.68%, -0.32%) in the placebo group (estimated treatment difference, -0.57%; 95% confidence interval: -0.79%, -0.36%; P < 0.001). The incidence of adverse events was similar between the two groups. There were no severe hypoglycemia events or drug-related serious adverse events in the dorzagliatin group. In summary, dorzagliatin improved glycemic control in drug-naive patients with T2D and showed a good tolerability and safety profile. The SEED study is a phase 3 clinical trial demonstrating a beneficial effect on glycemic control of dorzagliatin, a glucokinase activator, in drug-naive patients with newly diagnosed type 2 diabetes.

  • 推荐引用方式
    GB/T 7714：
    Zhu Dalong,Li Xiaoying,Ma Jianhua, et al. Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial [J].NATURE MEDICINE,2022,28(5):965-+.
  • APA：
    Zhu Dalong,Li Xiaoying,Ma Jianhua,Zeng Jiao''e,&Chen Li.(2022).Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial .NATURE MEDICINE,28(5):965-+.
  • MLA：
    Zhu Dalong, et al. "Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial" .NATURE MEDICINE 28,5(2022):965-+.
  • 条目包含文件：
    文件类型：PDF,文件大小：
    正在加载全文
浏览次数：76 下载次数：0
分享到：
浏览次数：76
下载次数：0
打印次数：0

网站总浏览量： 次   

Copyright © 中日友好医院

技术支持：北京同舟云网络信息技术有限公司

浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部